methyl 2-aminomethyl-1,3-thiazole-4-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 2-aminomethyl-1,3-thiazole-4-carboxylate
• 英文别名: 2-aminomethyl-thiazole-4-carboxylic acid methyl ester；methyl 2-(aminomethyl)-1,3-thiazole-4-carboxylate
• 化学式: C₆H₈N₂O₂S
• 分子量: 172.208
• InChiKey: BOLHSLRYXBDMHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  93.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl 2-(tert-butoxycarbonylaminomethyl)thiazole-4-carboxylate 在 盐酸 、 甲醇 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 12.58h， 以73%的产率得到methyl 2-aminomethyl-1,3-thiazole-4-carboxylate
  参考文献：
  名称：

  [EN] ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE
  [FR] MODULATEURS DE KINASES DE LYMPHOMES ANAPLASIQUES (ALK) ET METHODES D'UTILISATION

  摘要：

  本发明涉及公式I的化合物，其中L、X、Y、Z、R1、R2、R3和R4在此被定义。本发明还提供了使用这些化合物抑制激酶，更具体地抑制ALK激酶的方法。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动（如增殖、分化、程序性细胞死亡、迁移和化学入侵）的化合物。本发明的化合物抑制、调节和/或调节与上述细胞活动相关的激酶受体信号转导途径，本发明包括含有这些化合物的组合物和使用它们治疗激酶依赖性疾病和状况的方法；（公式I）。

  公开号：

  WO2005097765A1

文献信息

• [EN] AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS<br/>[FR] DERIVES DE CYANURE D'AZOLE METHYLIDENE ET LEUR UTILISATION COMME MODULATEURS DE PROTEINE KINASE
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003106455A1

  公开（公告）日：2003-12-24

  The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.

  本发明涉及唑衍生物，尤其是用作药物活性化合物的唑衍生物，以及包含这种唑衍生物的药物制剂。所述唑衍生物是蛋白激酶信号通路的调节剂，尤其是涉及c-Jun N端激酶和/或糖原合酶3的那一种。本发明还涉及新颖的唑衍生物以及它们的制备方法。X是O、S或NR0，其中R0是H或未取代或取代的C1-C6烷基；A是2-吡啶基，3-吡啶基，4-吡啶基，吡啶唑基，吡唑啉基，吡嗪基或三嗪基团。
• Anaplastic lymphoma kinase modulators and methods of use
  申请人：Exelixis, Inc.

  公开号：US07973061B2

  公开（公告）日：2011-07-05

  The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions; (Formula I).

  本发明涉及公式I的化合物，其中L、X、Y、Z、R1、R2、R3和R4在此定义。该发明还提供了使用这些化合物抑制激酶，更具体地是ALK激酶的方法。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学侵袭的化合物。本发明的化合物抑制、调节和/或调节与上述细胞活动相关的激酶受体信号转导途径，并且该发明包括含有这些化合物的组合物，以及使用它们治疗激酶依赖性疾病和病况的方法；（公式I）。
• NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Ferdinandy Péter

  公开号：US20130303572A1

  公开（公告）日：2013-11-14

  Compounds of general formula (I), salts or solvates thereof and pharmaceutical compositions containing same: wherein Z is N or CH or the Z(R1) part is replaced with a covalent bond, m and n is 0, 1, 2 or 3; HET is heteroaryl; X is CF 3 , halogen, CO-heterocyclyl, COOR3 or CONHR3; R1 is H, (CH 2 ) o -aryl, (CH 2 ) p -heteroaryl, (CH 2 ) q -biphenyl; C(O)—R5; S(O) 2 —R6; R2 is H, aryl, heteroaryl, Y—(CH 2 ) r -aryl, Y—(CH 2 ) s -heteroaryl, where some of the above substituents may be substituted; Y is O or S; with the exclusion of the compound where HET is 1,3-thiazol, X is COOH, R1 is 4-fluorophenyl and R2 is benzyloxy. The invention also relates to the use of a compound of general formula (I), salts or solvates thereof for the use in the prevention or treatment of diseases where the activation of MMPs is involved in the pathomechanism. In this aspect the use of the above excluded compound is also inventive.

  通式（I）的化合物，其盐或溶剂合物以及含有它们的药物组合物：其中Z为N或CH，或者Z（R1）部分被共价键替换，m和n为0、1、2或3；HET为杂环芳基；X为CF3、卤素、CO-杂环烷基、COOR3或CONHR3；R1为H、（CH2）o-芳基、（CH2）p-杂环芳基、（CH2）q-联苯基；C（O）-R5；S（O）2-R6；R2为H、芳基、杂环芳基、Y-（CH2）r-芳基、Y-（CH2）s-杂环芳基，其中一些上述取代基可能被取代；Y为O或S；不包括HET为1,3-噻唑，X为COOH，R1为4-氟苯基和R2为苄氧基的化合物。本发明还涉及使用通式（I）的化合物、其盐或溶剂合物用于预防或治疗涉及MMPs激活的病理机制的疾病。在这方面，上述被排除的化合物的使用也是创新的。
• ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE
  申请人：Leahy James William

  公开号：US20090186905A1

  公开（公告）日：2009-07-23

  The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R 1 , R 2 , R 3 and R 4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions; (Formula I).

  本发明涉及式I的化合物，其中L、X、Y、Z、R1、R2、R3和R4如本文所定义。本发明还提供使用这些化合物来抑制激酶，更具体地是ALK激酶的方法。本发明提供了用于调节蛋白激酶酶活性以调节细胞活动，如增殖、分化、程序性细胞死亡、迁移和化学入侵的化合物。本发明的化合物抑制、调节和/或调节与上述细胞活动变化相关的激酶受体信号转导通路，本发明包括含有这些化合物的组合物以及使用它们治疗激酶依赖性疾病和病状的方法；（式I）。
• The synthesis, N-alkylation and epimerisation study of a phthaloyl derived thiazolidine
  作者：Emma B. Veale、John E. O'Brien、Thomas McCabe、Thorfinnur Gunnlaugsson

  DOI：10.1016/j.tet.2008.04.097

  日期：2008.7

  The synthesis of the phthaloyl protected thiazolidine, N-phthaloyl-methyl-2(R)-thiazolidine-4(R)-methyl ester, 2, and a study of its susceptibility to epimerise in a range of solvents, using H-1 NMR spectroscopy, are described. Compound 2 was further reacted to yield the thiazole amino acid derivative, 3, and an N-alkylated thiazolidine derivative, 6, as a single diastereoisomer. The N-alkylation of 2, using mild bases, resulted in the formation of a mixture of diastereoisomers of 2 (2R,4R) and (2S,4R). Successful cleavage of the methyl ester and the phthaloyl protecting groups was achieved, giving rise to the formation of the two heterocyclic building blocks, 4 and 5. (c) 2008 Elsevier Ltd. All rights reserved.